Longevity Pipeline
Genflow Biosciences
SIRT6 (centenarian variant) gene therapy · MASLD / liver aging
IND-enablingAAV Gene Therapy
Mechanism
SIRT6 (centenarian variant) gene therapy
Intervention class
AAV gene therapy
Indication
MASLD / liver aging
Stage
IND-enabling
Evidence
animal
Funding
Euronext: GENF
Backers
Public
Overview
Delivers the centenarian SIRT6 variant to restore DNA-repair and metabolic function. Liver disease as first indication, lifespan as the thesis.
Technology
Genflow Biosciences works in AAV Gene Therapy — Using a hollowed-out virus to deliver a working gene.
Read the AAV Gene Therapy brief →Related companies
Company website / source ↗ Open the interactive map →
◢ Boom-cycle briefing
Get ahead of the next biotech boom.
New companies, stage changes, deal alerts and fresh tech briefs — one sharp email when the map moves.
Curated biotech intelligence, compiled for orientation — not investment advice. Company stages, deals and figures move fast; verify against ClinicalTrials.gov, company filings and primary sources before acting.